The United Laboratories International Holdings (HK:3933) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The United Laboratories International Holdings has announced that its Ceftazidime for Injection has passed the quality and efficacy consistency evaluation, strengthening its position in the anti-infective market. This product, a third-generation cephalosporin antibiotic, is used for a variety of infections and is included in China’s National Essential Drug List. The approval supports the company’s ongoing commitment to developing innovative healthcare solutions.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.